Kintor Pharma Included in Hong Kong Stock Connect Program

06 September 2021 | Monday | News


Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company's stock has been included in the Hong Kong Stock Connect program (the "Hong Kong Stock Connect"), effective September 6, 2021.
Image Source : Public Domain

Image Source : Public Domain

Dr. Youzhi Tong, Founder, Chairman, and Chief Executive Officer of Kintor Pharma, commented, "We are excited to be included in the Hong Kong Stock Connect. Since Kintor Pharma was officially listed on the Hong Kong Stock Exchange on May 22, 2020, the company's development has received long-term support from investors. We expect that the inclusion in the Stock Connect program will facilitate further expansion of our investor base and enhance the liquidity of our stock. We continue to advance the progress of our research and development, clinical operations, and commercialization efforts to innovate therapeutics for patients with unmet medical needs, help advance human health, and maximize value for our shareholders."

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close